Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Videos|December 10, 2020
Supplements and Featured Publications
- The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective
Full Video Abstract: Evidence for Oral Semaglutide in Type 2 Diabetes
This infographic to The American Journal of Managed Care® supplement, "The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective," describes key managed care information on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of type 2 diabetes in the United States, and appraises the clinical evidence for the first oral GLP-1RA, oral semaglutide.
Click
Articles in this issue
Related to this article
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
5